212 
Market Cap
Stock Chart
Heartware - 30 Day Poll
Recent BLOGS About Heartware Add New
Latest Company News
|
HeartWare Schedules Fourth Quarter Conference Call and Webcast
Sacramento Bee - Feb 6, 2012 By HeartWare International, Inc. FRAMINGHAM, Mass. and SYDNEY, Feb. 6, 2012 -- /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three and 12 months ended ...
|
|
HeartWare International, Inc. Receives Approval From U.S. Food And Drug Administration For The Third Patient Allotment
Reuters Key Development - Jan 24, 2011 |
|
HeartWare International, Inc. Files PMA Application For FDA Approval Of The HeartWare Ventricular Assist System For A Bridge-To-Transplant Indication
Reuters Key Development - Dec 28, 2010 |
|
HeartWare International, Inc. Announces Completion Of Concurrent Public Offerings Of Convertible Senior Notes and Common Stock
Reuters Key Development - Dec 15, 2010 |
|
HeartWare International, Inc. Announces Pricing Of Concurrent Public Offerings Of Convertible Senior Notes And Common Stock
Reuters Key Development - Dec 10, 2010 |
|
HeartWare International, Inc. Achieves Primary Endpoint With 92% Success In Pivotal Bridge-To-Transplant Clinical Trial, ADVANCE
Reuters Key Development - Nov 13, 2010 |
|
HeartWare International, Inc. Receives Second Patient Allotment Under Continued Access Protocol For Pivotal U.S. Bridge-To-Transplant Clinical Trial
Reuters Key Development - Sep 3, 2010 |
Website
Videos related to Heartware
Company Profile
Overview:
HeartWare develops and manufactures miniaturized implantable heart pumps, or Left Ventricular Assist Devices (LVADs), designed to treat patients suffering from advanced heart failure. The Company is developing the industry's smallest and blood contacting invasive pumps, which it believes will be the key to unlocking the potential of a large and underserved market.
The HeartWare(R) LVAD is a full-output pump designed to be implanted in the chest, avoiding the abdominal surgery generally required to implant competing devices.
The device is currently the subject of an international clinical trial involving five investigational centres in Europe and Australia. A clinical trial in the U.S. have begun. The device is commercially available in Europe. As of 2010 July over 400 implants had been achieved.
An Australian comapny with a signifiacnt part of its operations moved to theUSA.
Some key Financials:
Revenue 2009 calendar year: approx. $24 million
Cash as of Dec. 2009: approx. approx $50 million
Key Staff:
Douglas Godshall, Chief Executive Officer: Doug joined HeartWare as Chief Executive Officer in September 2006. An experienced medical device executive, Doug has overall responsibility for developing and executing HeartWare's strategic plan and for delivering key corporate, operational and financial objectives. Prior to joining HeartWare, Doug spent over 16 years at Boston Scientific, most recently as President of the Vascular Surgery Division.
James Schuermann, Vice President Sales and Marketing: Jim joined HeartWare in September 2007. He has overall responsibility for HeartWare's sales and marketing activities across all markets. Jim has over 16 years sales and marketing experience in the medical device arena. Prior to joining HeartWare, he spent nine years in sales and marketing at Boston Scientific Corporation.
Dr David Hathaway, Chief Medical Officer: David is responsible for all medical and clinical affairs, including the design and execution of HeartWare's clinical trial program. David was previously Vice President of Medical Affairs with Knoll Pharmaceutical Company until it was acquired by Abbott Laboratories.
Possible Competitiors:
- Thoratec
- Sunshine Heart